Asad Taherbhoy

Asad Taherbhoy" alt="Asad Taherbhoy" itemprop="image">

Company: Foghorn Therapeutics

Job title: Director of Drug Discovery

Seminars:

Targeting Transcription Factor-BAF Interactions in Cancer 10:00 am

Understanding how transcription factors make for compelling drug targets, but have been historically hard-to-drug Spotlighting transcription factors involvement with the BAF chromatin remodeling complex to open chromatin Developing a drug discovery platform to inhibit TF-BAF interactions; the Foghorn approachRead more

day: Day Two

PANEL DISCUSSION: 2022 & Beyond: Where Do We See the Epigenetics Drug Discovery & Development Landscape Over the Next 5 Years? 9:00 am

Outlining the successes of the past year in epigenetics drug development Reviewing novel approaches to targeting epigenetic regulators to diversify your pipeline Shedding light on the need to explore novel translational applications for epigenetic drugs to enter new indicationsRead more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.